详情页 - 四川省肿瘤医院知识库

当前位置：首页 > 详情页

Chimeric antigen receptor-engineered NK cells: new weapons of cancer immunotherapy with great potential

文献详情

资源类型：

Pubmed体系：

作者：

机构： [1]Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China [2]Department of Thoracic Oncology, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu 610041, China [3]Department of Oncology, Shanghai Tenth People’s Hospital, Tongji University School of Medicine, Shanghai 200072, China

出处：

DOI：

ISSN：

关键词： T cells Natural killer cells Chimeric antigen receptor Cancer Cellular immunotherapy

摘要：

Chimeric antigen receptor (CAR)-engineered T (CAR-T) cells have obtained prominent achievement in the clinical immunotherapy of hematological malignant tumors, leading to a rapid development of cellular immunotherapy in cancer treatment. Scientists are also aware of the prospective advantages of CAR engineering in cellular immunotherapy. Due to various limitations such as the serious side effects of CAR-T therapy, researchers began to investigate other immune cells for CAR modification. Natural killer (NK) cells are critical innate immune cells with the characteristic of non-specifically recognizing target cells and with the potential to become "off-the-shelf" products. In recent years, many preclinical studies on CAR-engineered NK (CAR-NK) cells have shown their remarkable efficacy in cancer therapy and their superiority over autologous CAR-T cells. In this review, we summarize the generation, mechanisms of anti-tumor activity and unique advantages of CAR-NK cells, and then analyze some challenges and recent clinical trials about CAR-NK cells therapy. We believe that CAR-NK therapy is a promising prospect for cancer immunotherapy in the future.© 2022. The Author(s).

基金：

语种：

PubmedID：

中科院(CAS)分区：

出版当年[2022]版：

大类 | 2 区医学

小类 | 2 区血液学 2 区肿瘤学

最新[2023]版：

大类 | 1 区医学

小类 | 2 区血液学 2 区肿瘤学

第一作者：

第一作者机构： [1]Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China

共同第一作者：

通讯作者：

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]Research advances in chimeric antigen receptor-modified T-cell therapy (Review). [2]嵌合抗原受体自然杀伤细胞免疫治疗多发性骨髓瘤研究进展 [3]GD2-specific chimeric antigen receptor-modified T cells targeting retinoblastoma - assessing tumor and T cell interaction. [4]Chimeric Antigen Receptor T Cells Targeting Cell Surface GRP78 to Eradicate Acute Myeloid Leukemia [5]GD2 chimeric antigen receptor modified T cells in synergy with sub-toxic level of doxorubicin targeting osteosarcomas. [6]HGF-Based CAR-T Cells Target Hepatocellular Carcinoma Cells That Express High Levels of c-Met [7]Natural killer cells as a double-edged sword in cancer immunotherapy: A comprehensive review from cytokine therapy to adoptive cell immunotherapy. [8]Invariant Natural Killer T Cells Ameliorate Monosodium Urate Crystal-Induced Gouty Inflammation in Mice. [9]New Approaches in CAR-T Cell Immunotherapy for Breast Cancer [10]The Role of Mesenchymal Stem Cells in Cancer Immunotherapy